Literature DB >> 2826619

Radioimmunodetection of melanoma: preliminary results of a prospective study.

G Buraggi1, A Turrin, N Cascinelli, A Attili, M Gasparini, L Callegaro, S Ferrone, E Seregni, E Bombardieri, F Belli.   

Abstract

A prospective study to evaluate the clinical usefulness of radioimmunodetection of melanoma in clinical practice is ongoing at the National Cancer Institute of Milan, Italy. Technical conditions for the application of the method were previously reported. In this trial, 99mTc-labelled F(ab')2 fragments of the 225.28S monoclonal antibody were used against a high molecular weight melanoma associated antigen (HMW-MAA). Retrospective studies on radioimmunodetection of melanoma have already been made by our group and by other Centers in about 300 patients. This study concerns the evaluation of the regional extension of primary melanoma. 23 patients with 32 suspected lymphatic involvements of melanoma on the trunk and arms underwent immunoscintigraphy. No false positive results were observed; 3 false negatives, one corresponding to a micrometastasis, were noticed. Specificity corresponds to 100% and sensitivity to 78.6%.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2826619     DOI: 10.1177/172460088600100108

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  4 in total

1.  Characterisation of ocular melanoma with cutaneous melanoma antibodies.

Authors:  J Bomanji; A Garner; J Prasad; D M Albert; J L Hungerford; M Granowska; K E Britton
Journal:  Br J Ophthalmol       Date:  1987-09       Impact factor: 4.638

2.  European multicentre study on melanoma immunoscintigraphy by means of 99mTc-labelled monoclonal antibody fragments. The European Multicentre Study Group.

Authors:  A G Siccardi; G L Buraggi; P G Natali; G A Scassellati; G Viale; S Ferrone
Journal:  Eur J Nucl Med       Date:  1990

3.  N-(2-diethylaminoethyl)-4-[123I]iodobenzamide as a tracer for the detection of malignant melanoma: simple synthesis, improved labelling technique and first clinical results.

Authors:  W Brandau; B Kirchner; P Bartenstein; J Sciuk; D Kamanabrou; O Schober
Journal:  Eur J Nucl Med       Date:  1993-03

4.  212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models.

Authors:  Benjamin B Kasten; Patsy G Oliver; Harrison Kim; Jinda Fan; Soldano Ferrone; Kurt R Zinn; Donald J Buchsbaum
Journal:  Int J Mol Sci       Date:  2018-03-21       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.